Abstract
Dofetilide is one of the several novel methanesulfonamide compounds that selectively inhibits the rapid component of the delayed rectifier potassium current, IKr, thus prolonging the effective refractory period (ERP) and the action potential duration (APD) in both the atria and the ventricles. It has no effects on sodium and calcium channels, and therefore, has minimal effects on myocardial conduction velocity. Dofetilide can be administered either orally or intravenously, and has a rapid onset of action. It was recently approved in the United States for the maintenance and conversion of normal sinus rhythm in patients with atrial fibrillation (AF).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
